Zepbound vs Mounjaro — same drug, same dose
Quick read · 5 min
Zepbound and Mounjaro are both tirzepatide made by Eli Lilly. Unlike Wegovy vs Ozempic, they use the same maximum dose (15mg weekly). But they have different FDA approvals: Zepbound for weight loss, Mounjaro for type 2 diabetes. This difference affects insurance coverage, pricing, and how they were studied — but not the drug itself.
- •Zepbound and Mounjaro are the same tirzepatide at the same 15mg maximum dose, but different FDA labels: Zepbound for weight loss, Mounjaro for diabetes
- •Both reach 15mg weekly — unlike Wegovy (2.4mg) vs Ozempic (2.0mg), there's no dose difference
- •Weight loss difference: Zepbound ~20.9%, Mounjaro ~13%. Same reason as semaglutide: people without diabetes lose more weight
- •Insurance covers Mounjaro for diabetes only. Zepbound is approved for weight loss and more likely to be covered
- •Both cost ~$1,069–$1,086/month at list price. LillyDirect vials for Zepbound: $349–$649/month (the better value)
Based on clinical trials · No rankings · Every claim linked to source
Same drug, different brand
Zepbound and Mounjaro both contain tirzepatide made by Eli Lilly. Unlike Wegovy vs Ozempic, they have identical maximum doses (15mg weekly). The difference is the FDA label: Zepbound is labeled for weight loss, Mounjaro for type 2 diabetes. This label difference affects insurance coverage and how they were tested, but not the drug.
Side by side
Zepbound
- Approved for: Weight loss in obesity and overweight with conditions
- Max dose: 15mg weekly
- Weight loss: ~20.9% average in trials
- Form: Weekly injection (use vials, not pens)
- Self-pay cost: $349–$649/month via LillyDirect
Mounjaro
- Approved for: Type 2 diabetes
- Max dose: 15mg weekly
- Weight loss: ~13% average in trials
- Form: Weekly injection
- List price: ~$1,069/month
Complete comparison
| Feature | Zepbound | Mounjaro |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA-approved use | Weight loss (obesity / overweight with conditions) | Type 2 diabetes |
| Max dose (weekly) | 15mg injection | 15mg injection |
| Weight loss in trials | ~20.9% (non-diabetics) | ~13% (people with diabetes) |
| Trial population | 2,539 adults with obesity, no diabetes | Adults with type 2 diabetes |
| Available forms | Injection only | Injection only |
| List price | ~$1,086/month | ~$1,069/month |
| LillyDirect savings | $349–$649/month (vials) | Discounts available; check pricing |
| Insurance coverage | If you have obesity / overweight with conditions | If you have type 2 diabetes |
Why does the same drug have two names?
Eli Lilly developed tirzepatide as a dual agonist — a new mechanism that targets both GLP-1 and GIP receptors. The company first pursued FDA approval for type 2 diabetes (Mounjaro) and later conducted trials for weight loss, securing a separate FDA approval (Zepbound).
Both brands are made by Eli Lilly from the same active ingredient at the same maximum dose (15mg weekly). What differs is the FDA label and indication:
- •FDA approval: Mounjaro for diabetes, Zepbound for weight loss
- •Insurance coverage: Each brand covered for its approved use only
- •Clinical evidence: Different trials with different populations
The key difference: identical maximum doses
Unlike Wegovy vs Ozempic, Zepbound and Mounjaro reach the same maximum dose: 15mg weekly. You might expect this to mean they produce identical weight loss results. But they don't — and here's why:
Population biology matters more than dose:
Tirzepatide 15mg produces ~20.9% weight loss in people with obesity (no diabetes). The same drug at the same dose produces ~13% weight loss in people with type 2 diabetes. The 8-point difference is not due to dose — both received 15mg. It's because people with diabetes lose less weight on GLP-1-family drugs. This is a well-established biological pattern across multiple medications.
So the comparison is straightforward: tirzepatide 15mg in non-diabetics produces ~20% weight loss (Zepbound trials). The same drug at the same dose in people with diabetes produces ~13% (Mounjaro trials). The drug is identical; the bodies responding to it are different.
The insurance reality
Since both drugs reach the same 15mg dose, some people wonder if they can use Mounjaro (diabetes brand) for weight loss and expect similar results to Zepbound. Insurance coverage tells the real story:
- 1.Mounjaro is labeled for diabetes. Using it for weight loss without diabetes is an off-label use.
- 2.Insurance covers approved indications. Most insurance plans cover Mounjaro for type 2 diabetes but not off-label for weight loss in non-diabetics.
- 3.Zepbound is the approved option. If you have obesity or overweight with a condition, Zepbound is FDA-approved for weight loss and more likely to be covered.
Bottom line: If you have obesity or overweight with a condition, ask your doctor about Zepbound. It's approved for weight loss and far more likely to be covered by insurance than an off-label use of Mounjaro.
Cost comparison
Both brands are similarly priced at list price. But Eli Lilly's LillyDirect program offers much lower pricing for Zepbound vials:
For self-pay patients, Zepbound vials via LillyDirect can be significantly cheaper than both brands at list price. Always ask your pharmacy for vials, not pens — vials are the same medication at a fraction of the cost.
Which should I ask my doctor about?
This depends on your health status and insurance:
If you have obesity (or overweight with a health condition):
Ask about Zepbound. It's FDA-approved for your condition and far more likely to be covered by insurance.
If you have both type 2 diabetes and obesity:
Your doctor may recommend Mounjaro (for diabetes management) or Zepbound (for weight loss). Both are appropriate — discuss which makes sense for your insurance and priorities.
If cost is a concern:
Explore Zepbound vials via LillyDirect, which can be $349/month at starting dose and $549–$599/month at typical maintenance — significantly cheaper than list price.
Next step most people take
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026